Matthew Klein
Chief Executive Officer at PTC THERAPEUTICS, INC.
Net worth: 7 M $ as of 2024-03-30
Profile
Matthew B.
Klein is currently the President, Chief Executive Officer & Director at PTC Therapeutics, Inc. He is also an Independent Director at Clearpoint Neuro, Inc. and a Clinical Associate Professor at Stanford University.
Previously, he served as the Chairman-Restorative Burn Surgery at the University of Washington.
He was also a Director at BioElectron Technology Corp.
from 2019 to 2020 and the Chief Medical Officer & Senior Vice President at Edison Pharmaceuticals, Inc. Dr. Klein completed his undergraduate degree at the University of Pennsylvania, his doctorate at Yale University, and his graduate degree at UW School of Public Health.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
PTC THERAPEUTICS, INC.
0.29% | 2024-04-18 | 225,807 ( 0.29% ) | 7 M $ | 2024-03-30 |
CLEARPOINT NEURO, INC.
0.05% | 2024-03-17 | 12,272 ( 0.05% ) | 83 450 $ | 2024-03-30 |
Matthew Klein active positions
Companies | Position | Start |
---|---|---|
CLEARPOINT NEURO, INC. | Director/Board Member | 2020-04-15 |
PTC THERAPEUTICS, INC. | Chief Executive Officer | 2023-03-21 |
Stanford University | Corporate Officer/Principal | - |
Former positions of Matthew Klein
Companies | Position | End |
---|---|---|
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Chief Executive Officer | 2018-12-31 |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Matthew Klein
University of Pennsylvania | Undergraduate Degree |
Yale University | Doctorate Degree |
UW School of Public Health | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PTC THERAPEUTICS, INC. | Health Technology |
CLEARPOINT NEURO, INC. | Health Technology |
Private companies | 2 |
---|---|
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Health Technology |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Commercial Services |
- Stock Market
- Insiders
- Matthew Klein